No insider purchase over the last 90 days. The latest, by 李方立, was filed 23 Mar 2026.
Sinotherapeutics Inc.: what insiders have been doing
Sinotherapeutics Inc., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to SSE / SZSE (CSRC). Over the twelve months to 4 November 2026, 2 filings were filed, from 1 insider.
Only purchases show up on the open market, 2 purchases in all worth €6,706, filed by 1 insider. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The buyers include 1 senior executive. The largest single trade was a purchase of €4,226 by 李方立, published on 23 March 2026.
The clock since the last published purchase (23 March 2026) now reads 230 days.
Across the 517 companies tracked on its exchange, the median is 2 filings; at 2 filings, this issuer sits right on that mark. The full history, which starts in 2026, counts 2 purchases against no sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and UCB. This summary is built from SSE / SZSE (CSRC) disclosures alone and does not predict where the share price will go.
Who traded when
BuySaleSince the insiders bought
- -15.1%Entry CN¥9.18 · Close 03 Nov 2026 CN¥7.79
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
About Sinotherapeutics Inc.
Xuantai Pharmaceutical is a company operating in the healthcare and pharmaceutical sector, listed on the Shanghai Stock Exchange. It specializes in the development and marketing of pharmaceutical products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
